Lumbar puncture performed.14Tongue fasciculation noted about exam. includes cerebrospinal fluid (CSF) assays. The second option often reveals lymphocytic pleocytosis or oligoclonal bands with normal to elevated CSF protein. CSF screening for anti-NMDAR antibodies facilitates diagnostic confirmation. Serum anti-NMDAR antibody assays are not as sensitive as CSF assays. Management includes symptomatic treatment and immunotherapy. Keywords: anti-NMDAR, autoimmune encephalitis, encephalitis, NMDA Intro Anti-N-methyl D-aspartate (NMDA) receptor (anti-NMDAR) encephalitis, caused by immunoreactivity against the NMDA receptor 1 (NR1) subunit of the NMDA receptor, is one of the most common autoimmune encephalitides, 1st explained in 2007 by Dalmau and colleagues in which psychiatric and neurologic symptoms were found in ladies with ovarian teratomas.1 The condition was later confirmed to be not exclusively paraneoplastic. Later on studies reported individuals afflicted without tumor involvement.2,3 Although available data suggest the disease is more prevalent in adult ladies, and in the non-Caucasian population, the condition has been explained in both genders, in multiple races, and throughout the life-span.4,5 However, increasing case reports of anti-NMDAR encephalitis in the psychiatric literature have shown the SGI-7079 significant overlap between neurologic and psychiatric pathology associated with autoimmune encephalitis.6C10 The clinical progression of the encephalitis has also been more thoroughly defined, having a multiphase model currently in use.11 The prodromal phase is suggestive of a viral flu-like illness, in which fever, malaise, and fatigue may be prominent. This phase varies in period and may also involve top respiratory or gastrointestinal symptoms. The condition is definitely often clinically acknowledged in the ensuing psychotic phase, in which delusions, hallucinations, paranoia, and agitation may be exhibited. During this phase, anti-NMDAR encephalitis is definitely often misdiagnosed like a main psychotic or substance-induced disorder. Following these psychotic symptoms is definitely EPHB4 often the progression to a state in which catatonia, impaired attention, dyskinesias, and seizures may develop. In addition, significant autonomic instability, with wide-ranging fluctuations in body temperature, blood pressure, respiratory rate, and cardiac rhythm, may occur.12 It is important to note that anti-NMDAR instances may not adhere to a strict phasic progression as mentioned earlier and may not include all the symptomatology pointed out earlier, thereby complicating diagnosis. Indeed, as autoimmune etiologies of psychiatric symptoms continue to be better recognized as a whole, patient presentations that should quick further immunologic evaluation have been recognized. Herken and Pruss13 have described yellow flag and reddish flag symptoms that are particularly indicative of an autoimmune process. Decreased level of consciousness, abnormal postures/motions, autonomic instability, focal neurologic deficits, aphasia/dysarthria, and quick progression of psychosis despite therapy, hyponatremia, catatonia, headache, and presence of additional autoimmune disease were described as yellow flag (i.e., raising suspicion) indicators of an autoimmune process. Cerebrospinal fluid (CSF) pleocytosis and oligoclonal bands without illness, generalized seizures, faciobrachial seizures, suspected neuroleptic malignant syndrome (NMS), magnetic resonance imaging (MRI) abnormalities (mesiotemporal hyperintensities, atrophy pattern), and electroencephalogram (EEG) abnormalities (slowing, epileptic activity or intense delta brush) are of actually higher (reddish flag) concern signals of potential autoantibody involvement. Identification of these characteristics is associated SGI-7079 with SGI-7079 earlier diagnosis, implementation of immunotherapy, and improved individual outcomes. In the following case statement, we discuss a patient who presented to the emergency division (ED) with behavioral symptoms and who was later medically hospitalized with psychiatric and neurologic discussion. Described are the multiphase phenomena, as well as the coordination of the psychiatry, neurology, and internal medicine solutions in diagnosing the unusual symptoms of this still poorly recognized disease entity. Patient details have been de-identified to ensure privacy. Case Statement The patient was a 40-year-old African-American woman without earlier psychiatric history and a medical history of hypertension. She was brought to the ED by her family, who were concerned about the sudden onset of unusual behavior. She had been sent home from work earlier that day time due to failure to total her normal jobs. Her son mentioned that she was not making sense, becoming forgetful and not acting like herself. The patient reportedly smoked cannabis after she arrived home. However, her child indicated her behavior was odd actually before her drug use and then worsened during the day, prompting medical attention. Her family reported a recent stressor of the death of her mother several months earlier. The patient was notably agitated in the ED, appeared puzzled, and tried to leave. She was given intramuscular ziprasidone and lorazepam to calm her. Initial laboratory studies included a comprehensive metabolic panel and a complete blood count, both of which were unremarkable. Her alcohol level was zero, and her urine drug display was positive for cannabinoids only. Computed tomography of her mind was negative for any acute process (Table 1). She was placed.